FORM PTO-1449 SERIAL NO. U. S DEPARTMENT OF COMMERCE ATTY. DOCKET NO. PATENT AND TRADEMARK OFFICE 10/749,932 U 104681-4 INFORMATION DISCLOSURE APPLICANT STATEMENT BY APPLICANT Prasad K. Deshpande, et al. (Use several sheets if necessary). **GROUP** FILING DATE 12/31/2003 1614 REFERENCE DESIGNATION U.S. PATENT DOCUMENTS **EXAMINER** FILING DATE IF DOCUMENT · INITIAL APPROPRIATE NUMBER DATE NAME AA 6,329,391 12/2001 Ledoussal et al. AB 4,382,892 05/1983 Hayakawa et al. AC 01/1999 5,859,026 Ito et al. 03 🌌 1999 AD 5,889,009 Miyake et al. 6,121,285 ΑE 09/2000 Takemura et al. AF 6,184,388 02/2001 Takemura et al. AG 3,984,403 10/1976 Fujisawa et al. FOREIGN PATENT DOCUMENTS DOCUMENT **TRANSLATION** NUMBER DATE COUNTRY YES NO M AH 0394553 06/1995 EP X CA ΑI 0572259 12/1993 EΡ AJ 0287951 10/1988 ĘΡ OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.) European Patent Specification 0394553 B1, dated June 21, 1995 ΑK Alsina J. et al. "Active Carbonate Resins for Solid-Phase Synthesis Through the Anchoring of a ΑL Hydroxyl Function. Synthesis of Cyclic and Alcohol Peptides", Tetrahedron Letters, (1997), 38(5): 883-886 Edwards W.B. et al. "Generally Applicable, Convenient Solid-Phase Synthesis and Receptor Affinities of Octreotide Analogs", J. Med. Chem., (1994), 37(22): 3749-3757 Dhople, A.M. and M.A. Tbanez. "In vivo susceptibility of mycobacterium leprae to ofloxacin either singly or in combination with Rifampicin and Rifabutin", Arzneimittel-Forschung,, (1994), 44(4): 563-565 Haustein U.F. et al. "Topical quinolone nadifloxacin (OPC-7251) in bacterial skin disease: clinical AO evaluation in a multicenter open trial and in vitro antimicrobiological susceptibility testing", J. Dermatological Treatment, (1997), 8: 87-92 Hashimoto, Koji et al. "A Practical Synthesis of (S)-(-)-Nadifloxacin: Novel Acid-Catalyzed Racemization of Tetrahydroquinaldine Derivative", Chem. Pharm. Bull., (1996), 44(4): 642-645 Irish, D. et al. "Control of an outbreak of an epidemic methicillin-resistant Staphylococcus aureus also AQ resistant to mupirocin", J. Hospital Infection, (1998), 39: 19-26 **EXAMINER** DATE CONSIDERED **EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through

citation if not in conformance and not considered. Include copy of this form with next communication to

applicant.

11|51|00 TG